Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two FDAs Rejected By Rep. Waxman, Says Fixing Food Safety Is First Priority

Executive Summary

The idea to divide FDA into two separate agencies - one that regulates drugs and devices and another that regulates foods - was dismissed by House Energy and Commerce Chairman Henry Waxman as the wrong priority for Congress and the agency

You may also be interested in...

FDA Appropriators Discuss Ending The Food & Drug Administration

Splitting food authorities out of FDA suggested by Wyoming Republican Cynthia Lummis as the House Appropriations Agriculture/FDA subcommittee queries FDA Commissioner Margaret Hamburg on FY 2013 funding.

FDA Commissioner Hamburg: White House Close To Formal Announcement

Former New York City Health Commissioner Margaret Hamburg is preparing for her confirmation hearings as FDA commissioner, with the White House set to announce her nomination shortly

FLAVORx Hopes A Spray-Full Of Pill Glide Helps The Medicine Go Down

FLAVORx designed its flavored Pill Glide Swallowing Sprayto help consumers take difficult-to-swallow or unpleasant-tasting pills





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts